A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli.

[1]  W. Zeng,et al.  A Modular Approach to Assembly of Totally Synthetic Self-adjuvanting Lipopeptide-based Vaccines Allows Conformational Epitope Building* , 2011, The Journal of Biological Chemistry.

[2]  D. Doolan,et al.  Non-toxic derivatives of LT as potent adjuvants. , 2011, Vaccine.

[3]  Weiping Zhang,et al.  Genetic Fusions of Heat-Labile Toxoid (LT) and Heat-Stable Toxin b (STb) of Porcine Enterotoxigenic Escherichia coli Elicit Protective Anti-LT and Anti-STb Antibodies , 2010, Clinical and Vaccine Immunology.

[4]  P. Puntervoll,et al.  Heat-Stable Enterotoxin of Enterotoxigenic Escherichia coli as a Vaccine Target , 2010, Infection and Immunity.

[5]  D. Jackson,et al.  Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys , 2010, Amino Acids.

[6]  H. Dupont,et al.  Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial , 2008, The Lancet.

[7]  A. Kelso,et al.  Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses. , 2008, Vaccine.

[8]  R. Roden,et al.  Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2 , 2008, Proceedings of the National Academy of Sciences.

[9]  P. Doherty,et al.  The Context of Epitope Presentation Can Influence Functional Quality of Recalled Influenza A Virus-Specific Memory CD8+ T Cells1 , 2007, The Journal of Immunology.

[10]  D. Jackson,et al.  The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function. , 2007, Molecular immunology.

[11]  R. Walker,et al.  Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. , 2007, Vaccine.

[12]  D. Jackson,et al.  Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization. , 2006, The Journal of infectious diseases.

[13]  K. Kedzierska,et al.  Intranasal lipopeptide primes lung‐resident memory CD8+ T cells for long‐term pulmonary protection against influenza , 2006, European journal of immunology.

[14]  D. Jackson,et al.  Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. , 2005, Vaccine.

[15]  J. Holmgren,et al.  Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. , 2005, Current opinion in immunology.

[16]  N. Beeching,et al.  Traveller's diarrhoea. , 2005, The Lancet. Infectious diseases.

[17]  Corey Smith,et al.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Y. Shimonishi,et al.  Structural features of Escherichia coli heat-stable enterotoxin that activates membrane-associated guanylyl cyclase. , 2004, The journal of peptide research : official journal of the American Peptide Society.

[19]  L. Brown,et al.  Highly Immunogenic and Totally Synthetic Lipopeptides as Self-Adjuvanting Immunocontraceptive Vaccines1 , 2002, The Journal of Immunology.

[20]  B. Gaillard-Martinie,et al.  Full Capacity of Recombinant Escherichia coliHeat-Stable Enterotoxin Fusion Proteins for Extracellular Secretion, Antigenicity, Disulfide Bond Formation, and Activity , 2000, Infection and Immunity.

[21]  B. Guy,et al.  Parenteral Adjuvant Activities of Escherichia coli Heat-Labile Toxin and Its B Subunit for Immunization of Mice against Gastric Helicobacter pyloriInfection , 2000, Infection and Immunity.

[22]  James P. Nataro,et al.  Diarrheagenic Escherichia coli , 1998, Clinical Microbiology Reviews.

[23]  E. Holmgren,et al.  A recombinant Escherichia coli heat-stable enterotoxin (STa) fusion protein eliciting anti-STa neutralizing antibodies. , 1991, FEMS microbiology letters.

[24]  J. Holmgren,et al.  Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination. , 1990, Research in microbiology.

[25]  J. Clements,et al.  Construction of a nontoxic fusion peptide for immunization against Escherichia coli strains that produce heat-labile and heat-stable enterotoxins , 1990, Infection and immunity.

[26]  J. Holmgren,et al.  Genetic fusion of a non‐toxic heat‐stable enterotoxin‐related decapeptide antigen to cholera toxin B‐subunit , 1988, FEBS letters.

[27]  J. Holmgren,et al.  Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay , 1986, Journal of clinical microbiology.

[28]  Y. Takeda,et al.  Essential structure for full enterotoxigenic activity of heat‐stable enterotoxin produced by enterotoxigenic Escherichia coli , 1985, FEBS letters.

[29]  R. Guerrant,et al.  Effects of Escherichia coli heat-stable enterotoxin STb on intestines of mice, rats, rabbits, and piglets , 1984, Infection and immunity.

[30]  R. Houghten,et al.  Protection against human and porcine enterotoxigenic strains of Escherichia coli in rats immunized with a cross-linked toxoid vaccine , 1983, Infection and immunity.

[31]  R. Houghten,et al.  Vaccine for enterotoxigenic Escherichia coli based on synthetic heat-stable toxin crossed-linked to the B subunit of heat-labile toxin. , 1983, The Journal of infectious diseases.

[32]  M. Levine,et al.  Effect of chlorpromazine on intestinal secretion mediated by Escherichia coli heat-stable enterotoxin and 8-Br-cyclic GMP in infant mice. , 1981, Gastroenterology.

[33]  D. Nalin,et al.  Immunity to Enterotoxigenic Escherichia coli , 1979, Infection and immunity.

[34]  H. Dupont,et al.  Humoral immune response to the heat-labile enterotoxin of Escherichia coli in naturally acquired diarrhea and antitoxin determination by passive immune hemolysis , 1977, Infection and immunity.

[35]  E. Boedeker.  Gastrointestinal infections: an overview. , 2004, Current opinion in gastroenterology.

[36]  T. Hirst,et al.  Recombinant enterotoxins as vaccines against Escherichia coli-mediated diarrhoea. , 1993, Vaccine.

[37]  E. Power,et al.  Uptake of L-[14C]-alanine by glutaraldehyde-treated and untreated spores of Bacillus subtilis. , 1990, FEMS microbiology letters.

[38]  M. Field.  Mechanisms of action of cholera and Escherichia coli enterotoxins. , 1979, The American journal of clinical nutrition.